{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:24Z","timestamp":1794047484107,"version":"4.8.0"},"reference-count":14,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.286279","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T11:06:11Z","timestamp":1728558371000},"page":"784-790","source":"Crossref","is-referenced-by-count":0,"title":["HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics"],"prefix":"10.3324","volume":"110","author":[{"given":"Cristina","family":"Florean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Lernoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lorant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Losson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Bormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schnekenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Diederich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"73521","doi-asserted-by":"crossref","unstructured":"Monteith BE, Sandhu I, Lee AS. Management of multiple myeloma: a review for general practitioners in oncology. Curr Oncol. 2023; 30(5):4382-4401.","DOI":"10.3390\/curroncol30050334"},{"key":"73522","doi-asserted-by":"crossref","unstructured":"Yee AJ, Raje NS. Panobinostat and multiple myeloma in 2018. Oncologist. 2018; 23(5):516-517.","DOI":"10.1634\/theoncologist.2017-0644"},{"key":"73523","doi-asserted-by":"crossref","unstructured":"Imai Y, Hirano M, Kobayashi M, Futami M, Tojo A. HDAC inhibitors exert anti-myeloma effects through multiple modes of action. Cancers (Basel). 2019; 11(4):475.","DOI":"10.3390\/cancers11040475"},{"key":"73524","doi-asserted-by":"crossref","unstructured":"Vogl DT, Raje N, Jagannath S. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res. 2017; 23(13):3307-3315.","DOI":"10.1158\/1078-0432.CCR-16-2526"},{"key":"73525","doi-asserted-by":"crossref","unstructured":"Lernoux M, Schnekenburger M, Dicato M, Diederich M. Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors. Biochem Pharmacol. 2021; 188:114526.","DOI":"10.1016\/j.bcp.2021.114526"},{"key":"73526","doi-asserted-by":"crossref","unstructured":"Zhou X, Rasche L, Kortum KM, Mersi J, Einsele H. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2023; 108(4):958-968.","DOI":"10.3324\/haematol.2020.266841"},{"key":"73527","doi-asserted-by":"crossref","unstructured":"Zeleke TZ, Pan Q, Chiuzan C. Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nat Cancer. 2023; 4(2):257-275.","DOI":"10.1038\/s43018-022-00489-5"},{"key":"73528","doi-asserted-by":"crossref","unstructured":"Bhalla S, Melnekoff DT, Aleman A. Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. Sci Adv. 2021; 7(47):eabg9551.","DOI":"10.1126\/sciadv.abg9551"},{"key":"73529","doi-asserted-by":"crossref","unstructured":"Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc. 2010; 132(31):10842-10846.","DOI":"10.1021\/ja102758v"},{"key":"73530","doi-asserted-by":"crossref","unstructured":"Ziccheddu B, Da Via MC, Lionetti M. Functional impact of genomic complexity on the transcriptome of multiple myeloma. Clin Cancer Res. 2021; 27(23):6479-6490.","DOI":"10.1158\/1078-0432.CCR-20-4366"},{"key":"73531","doi-asserted-by":"crossref","unstructured":"Shultz MD, Cao X, Chen CH. Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. J Med Chem. 2011; 54(13):4752-4772.","DOI":"10.1021\/jm200388e"},{"key":"73532","doi-asserted-by":"crossref","unstructured":"Jaenicke LA, von Eyss B, Carstensen A. Ubiquitin-dependent turnover of MYC antagonizes MYC\/PAF1C complex accumulation to drive transcriptional elongation. Mol Cell. 2016; 61(1):54-67.","DOI":"10.1016\/j.molcel.2015.11.007"},{"key":"73533","doi-asserted-by":"crossref","unstructured":"Mitsiades CS, Mitsiades NS, McMullan CJ. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004; 101(2):540-545.","DOI":"10.1073\/pnas.2536759100"},{"key":"73534","doi-asserted-by":"crossref","unstructured":"Ramkumar P, Abarientos AB, Tian R. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. Blood Adv. 2020; 4(13):2899-2911.","DOI":"10.1182\/bloodadvances.2019001346"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286279\/77619","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286279\/78140","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11785\/77619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:24Z","timestamp":1794046044000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.286279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286279","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,10]]}}}